Acetazolamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Acetazolamide
- Pharmacist Assessment Report
- Acetazolamide: carbonic anhydrase inhibitor → Exercise-induced malignant hyperthermia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Acetazolamide: carbonic anhydrase inhibitor → Exercise-induced malignant hyperthermia
One-Sentence Summary
Acetazolamide is an oral carbonic anhydrase inhibitor marketed in Australia as Diamox tablets. The TxGNN model predicts it may be effective for exercise-induced malignant hyperthermia, with a score of 0.9995. However, there are 0 clinical trials and 0 publications supporting this prediction, so it rests on computational prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Exercise-induced malignant hyperthermia |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Acetazolamide is known as a carbonic anhydrase inhibitor, which alters acid-base balance and ion handling.
A possible link to exercise-induced malignant hyperthermia is that these changes might influence muscle ion handling and the body’s response to exertion. This is speculative: no study in the compiled data tests the idea, and the relationship between the drug’s known actions and this condition has not been established. The high score should be treated as a hypothesis for further investigation, not as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 1004W | Diamox | Tablet 250 mg | Not recorded in the local data |
Safety Considerations
Safety information in the compiled data is limited to drug interaction screening. Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Drug interactions (100 interactions were identified; examples below):
- Major: acetylsalicylic acid (aspirin), cisapride
- Moderate: antidiabetic agents (e.g. acarbose, acetohexamide, alogliptin, canagliflozin, chlorpropamide, dapagliflozin, dulaglutide), corticosteroids (e.g. beclomethasone, betamethasone, dexamethasone), amphotericin B formulations, and laxatives (bisacodyl, castor oil)
- Minor: doxycycline
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high score but no supporting clinical trials, publications or defined mechanism (Evidence Level L5). A recommendation to proceed cannot be justified on model output alone.
To proceed, the following is needed:
- Mechanism of action data and a plausible, testable pathway linking carbonic anhydrase inhibition to exercise-induced malignant hyperthermia
- Preclinical or clinical studies that directly address this condition
- TGA Product Information review for warnings, contraindications and approved-use details
- A safety assessment for the target population, including the drug interactions identified above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.